NZ212691A - Pharmaceutical composition containing refined detoxified endotoxin - Google Patents
Pharmaceutical composition containing refined detoxified endotoxinInfo
- Publication number
- NZ212691A NZ212691A NZ212691A NZ21269185A NZ212691A NZ 212691 A NZ212691 A NZ 212691A NZ 212691 A NZ212691 A NZ 212691A NZ 21269185 A NZ21269185 A NZ 21269185A NZ 212691 A NZ212691 A NZ 212691A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- warm
- onset
- blooded
- inhibiting
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 241001465754 Metazoa Species 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 206010040047 Sepsis Diseases 0.000 claims description 16
- 208000013223 septicemia Diseases 0.000 claims description 16
- 241000699670 Mus sp. Species 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 10
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- KYQCXUMVJGMDNG-UHFFFAOYSA-N 4,5,6,7,8-pentahydroxy-2-oxooctanoic acid Chemical compound OCC(O)C(O)C(O)C(O)CC(=O)C(O)=O KYQCXUMVJGMDNG-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 11
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 231100000284 endotoxic Toxicity 0.000 description 4
- 230000002346 endotoxic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/630,013 US4629722A (en) | 1984-07-12 | 1984-07-12 | Method of inhibiting the onset of acute radiation syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ212691A true NZ212691A (en) | 1988-02-12 |
Family
ID=24525404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ212691A NZ212691A (en) | 1984-07-12 | 1985-07-09 | Pharmaceutical composition containing refined detoxified endotoxin |
Country Status (14)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US5354782A (en) * | 1991-01-17 | 1994-10-11 | Merrell Dow Pharmaceuticals Inc. | Polyamine phenols as radioprotective agents |
| AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
| US5530113A (en) * | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
| TWI494125B (zh) | 2009-06-05 | 2015-08-01 | Infectious Disease Res Inst | 合成的葡萄吡喃糖基脂質佐劑 |
| NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| AU2013262691B2 (en) | 2012-05-16 | 2018-12-20 | Immune Design Corp. | Vaccines for HSV-2 |
| WO2017039751A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| SG11201508092YA (en) | 2013-04-18 | 2015-10-29 | Immune Design Corp | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| CA2961375A1 (en) * | 2014-09-16 | 2016-03-24 | Bioincept, Llc | Compositions and methods for treating acute radiation syndrome |
| EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| KR101909660B1 (ko) * | 2017-07-06 | 2018-10-18 | 이보미 | 안경알 자판기 서비스 제공 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1188519A (en) * | 1966-10-27 | 1970-04-15 | Wellcome Found | Method for the Purification of Lipopolysaccharides |
| US4435386A (en) * | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| CA1225592A (en) * | 1983-08-26 | 1987-08-18 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
-
1984
- 1984-07-12 US US06/630,013 patent/US4629722A/en not_active Expired - Lifetime
-
1985
- 1985-07-09 NZ NZ212691A patent/NZ212691A/en unknown
- 1985-07-10 AU AU44758/85A patent/AU556971B2/en not_active Ceased
- 1985-07-11 NL NL8501995A patent/NL8501995A/nl not_active Application Discontinuation
- 1985-07-11 FR FR8510629A patent/FR2567403A1/fr not_active Withdrawn
- 1985-07-11 GB GB08517545A patent/GB2161381B/en not_active Expired
- 1985-07-11 ZA ZA855243A patent/ZA855243B/xx unknown
- 1985-07-12 DE DE19853524992 patent/DE3524992A1/de active Granted
- 1985-07-12 BE BE0/215338A patent/BE902875A/fr not_active IP Right Cessation
- 1985-07-12 CH CH3039/85A patent/CH665355A5/de not_active IP Right Cessation
- 1985-07-12 DE DE3546592A patent/DE3546592C2/de not_active Expired
- 1985-07-12 IT IT8548347A patent/IT1214671B/it active
- 1985-07-12 KR KR1019850004992A patent/KR880000191B1/ko not_active Expired
- 1985-07-12 IL IL75789A patent/IL75789A/xx unknown
- 1985-07-12 JP JP60152571A patent/JPS6193123A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2161381A (en) | 1986-01-15 |
| BE902875A (fr) | 1985-11-04 |
| DE3546592C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-06-01 |
| IL75789A0 (en) | 1985-11-29 |
| US4629722A (en) | 1986-12-16 |
| AU4475885A (en) | 1986-01-16 |
| FR2567403A1 (fr) | 1986-01-17 |
| IL75789A (en) | 1990-04-29 |
| AU556971B2 (en) | 1986-11-27 |
| KR860000867A (ko) | 1986-02-20 |
| NL8501995A (nl) | 1986-02-03 |
| CH665355A5 (de) | 1988-05-13 |
| IT8548347A0 (it) | 1985-07-12 |
| GB8517545D0 (en) | 1985-08-14 |
| KR880000191B1 (ko) | 1988-03-12 |
| IT1214671B (it) | 1990-01-18 |
| JPS6234733B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-07-28 |
| GB2161381B (en) | 1988-01-13 |
| DE3524992C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-05-11 |
| ZA855243B (en) | 1986-02-26 |
| JPS6193123A (ja) | 1986-05-12 |
| DE3524992A1 (de) | 1986-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4629722A (en) | Method of inhibiting the onset of acute radiation syndrome | |
| US5736519A (en) | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide | |
| JPS6137739A (ja) | 免疫グロブリン類および治療剤を配合した医薬組成物 | |
| US20240018258A1 (en) | Cd47 blockade therapy with cd38 antibody | |
| US10232010B2 (en) | Compositions and methods for treatment of radiation exposure | |
| EP0488718B1 (en) | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine | |
| Maheshwari et al. | Interferon inhibits Aspergillus fumigatus growth in mice: an activity against an extracellular infection | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| Bui et al. | Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs | |
| DE69532557T2 (de) | Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene | |
| Hiddemann et al. | Mantle cell lymphoma: therapeutic strategies are different from CLL | |
| EP0483643B1 (en) | Use of macrophage colony-stimulating factor in the treatment of cachexia | |
| Crooks et al. | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | |
| EP1425303A2 (de) | Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems | |
| EP0670165B1 (en) | Use of seminal ribonuclease as antimetastatic compound | |
| DE3643001A1 (de) | Pharmazeutische zusammensetzung | |
| EP0391224A2 (de) | Arzneimittel und ihre Verwendung zur Behandlung von Parasitosen | |
| Mansour et al. | Effect of methotrexate on the response of rat lymphocytes to phytohaemagglutinin | |
| JP2008128819A (ja) | 花粉症に対する予防又は治療作用を有する物質の評価方法及びスクリーニング方法、並びに、花粉症の予防又は治療のための薬剤及びその製造方法 | |
| JPH0331215A (ja) | 制癌療法支持剤 | |
| KR20220020304A (ko) | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 | |
| Hellmann et al. | Effect of high dose mitozantrone with Cronassial on the Lewis lung carcinoma and L1210 leukaemia | |
| WO2001028581A1 (fr) | Compositions medicinales pouvant inhiber gvhd | |
| EA | K&hmi M, Fijita H, Haneda H, Akita H, Kuzumaki N, MiyPmoto H et Pl. Laboratory ojhfolecular Genetics, Cancer Insritute, H&aid0 | |
| CN1688332A (zh) | 成骨生长肽对红系造血组细胞的促增殖作用及应用 |